Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q6535765> ?p ?o }
Showing triples 1 to 32 of
32
with 100 triples per page.
- Q6535765 subject Q8715619.
- Q6535765 abstract "Levodopa-induced dyskinesia is a form of dyskinesia associated with levodopa used to treat Parkinson's disease. It often involves hyperkinetic movements, including chorea, dystonia, and athetosis.In the context of Parkinson's disease (PD), dyskinesia is often the result of chronic L-DOPA (levodopa) therapy. These motor fluctuations occur in more than half of PD patients after 5–10 years of L-DOPA treatment, with the percentage of affected patients increasing over time. Based on the relationship with levodopa dosing, dyskinesia most commonly occurs at the time of peak L-DOPA plasma concentrations and is thus referred to as peak-dose dyskinesia (PDD). As patients advance, they may evidence diphasic dyskinesia (DD), which occur when the drug concentration rises or falls. If dyskinesia becomes too severe or impairs the patient's quality of life, a reduction in L-Dopa might be necessary, however this may be accompanied by a worsening of motor performance. Therefore, once established, LID is difficult to treat. Amongst pharmacological treatment, N-methyl-D-aspartate (NMDA) antagonist, (a glutamate receptor), amantadine, has been proven to be clinically effective in a small number of placebo controlled randomized controlled trials, while many others have only shown promise in animal models. Attempts to moderate dyskinesia by the use of other treatments such as bromocriptine (Parlodel), a dopamine agonist, appears to be ineffective. In order to avoid dyskinesia, patients with the young-onset form of the disease or young-onset Parkinson's disease (YOPD) are often hesitant to commence L-DOPA therapy until absolutely necessary for fear of suffering severe dyskinesia later on. Alternatives include the use of DA agonists (i.e. ropinirole or pramipexole) in lieu of early L-DOPA use which delays the use of L-DOPA. Additionally, a review (Stocchi, F., Clin Neuropharmacol, 2010, 33, 198) shows that highly soluble L-DOPA prodrugs may be effective in avoiding the in vivo blood concentration swings that potentially lead to motor fluctuations and dyskinesia.".
- Q6535765 wikiPageWikiLink Q1076421.
- Q6535765 wikiPageWikiLink Q11085.
- Q6535765 wikiPageWikiLink Q1319792.
- Q6535765 wikiPageWikiLink Q170475.
- Q6535765 wikiPageWikiLink Q1759633.
- Q6535765 wikiPageWikiLink Q17929096.
- Q6535765 wikiPageWikiLink Q2298489.
- Q6535765 wikiPageWikiLink Q300989.
- Q6535765 wikiPageWikiLink Q3579672.
- Q6535765 wikiPageWikiLink Q3686031.
- Q6535765 wikiPageWikiLink Q409761.
- Q6535765 wikiPageWikiLink Q413581.
- Q6535765 wikiPageWikiLink Q417227.
- Q6535765 wikiPageWikiLink Q420510.
- Q6535765 wikiPageWikiLink Q4318555.
- Q6535765 wikiPageWikiLink Q507154.
- Q6535765 wikiPageWikiLink Q5266827.
- Q6535765 wikiPageWikiLink Q576618.
- Q6535765 wikiPageWikiLink Q600203.
- Q6535765 wikiPageWikiLink Q618076.
- Q6535765 wikiPageWikiLink Q629444.
- Q6535765 wikiPageWikiLink Q632856.
- Q6535765 wikiPageWikiLink Q6589598.
- Q6535765 wikiPageWikiLink Q755524.
- Q6535765 wikiPageWikiLink Q79749.
- Q6535765 wikiPageWikiLink Q828130.
- Q6535765 wikiPageWikiLink Q8715619.
- Q6535765 wikiPageWikiLink Q906492.
- Q6535765 comment "Levodopa-induced dyskinesia is a form of dyskinesia associated with levodopa used to treat Parkinson's disease. It often involves hyperkinetic movements, including chorea, dystonia, and athetosis.In the context of Parkinson's disease (PD), dyskinesia is often the result of chronic L-DOPA (levodopa) therapy. These motor fluctuations occur in more than half of PD patients after 5–10 years of L-DOPA treatment, with the percentage of affected patients increasing over time.".
- Q6535765 label "Levodopa-induced dyskinesia".